Skip to main content
Top
Published in: Neurological Sciences 1/2010

Open Access 01-06-2010 | Key Note Lecture

New acute treatments for headache

Author: Alan M. Rapoport

Published in: Neurological Sciences | Special Issue 1/2010

Login to get access

Abstract

Although we have several acute care medications for the treatment of migraine, we are always looking for new medications to treat our patients. Patients often say that their headaches are not under optimal control and would be happy to try another medication. Patients look for faster onset of relief, more complete relief, no recurrent headache and no adverse events. This article will cover some new and some anticipated acute care products, CGRP antagonists, sumatriptan by iontophoretic patch, sumatriptan by needle-free injections, DHE by oral inhalation and diclofenac potassium in a sachet. Botulinum toxin therapy, although a preventive measure, will be mentioned at the end.
Literature
1.
2.
go back to reference Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56PubMedCrossRef Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56PubMedCrossRef
3.
go back to reference Levy D, Burstein R, Strassman AM (2005) Calcitonin gene related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58:698–705PubMedCrossRef Levy D, Burstein R, Strassman AM (2005) Calcitonin gene related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58:698–705PubMedCrossRef
4.
go back to reference Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedCrossRef Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedCrossRef
5.
go back to reference Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–1312PubMedCrossRef Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–1312PubMedCrossRef
6.
go back to reference Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2089–2090CrossRef Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2089–2090CrossRef
7.
go back to reference Rapoport AM (2009) Antimigraine drugs: new frontiers. Neurol Sci 30(Suppl 1):S49–S54 (some of the above text is borrowed in entirety from Neurol Sci) Rapoport AM (2009) Antimigraine drugs: new frontiers. Neurol Sci 30(Suppl 1):S49–S54 (some of the above text is borrowed in entirety from Neurol Sci)
8.
go back to reference Pierce M, Marbury T, O’Neill C et al (2008) A novel patch formulation of sumatriptan succinate utilizing SmartRelief™ transdermal technology. Data presented at the 50th annual scientific meeting of the American Headache Society 28 June 2008 Pierce M, Marbury T, O’Neill C et al (2008) A novel patch formulation of sumatriptan succinate utilizing SmartRelief™ transdermal technology. Data presented at the 50th annual scientific meeting of the American Headache Society 28 June 2008
9.
go back to reference Armer T, Shrewsbury S, Newman S et al (2007) Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 23:3177–3187PubMedCrossRef Armer T, Shrewsbury S, Newman S et al (2007) Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 23:3177–3187PubMedCrossRef
10.
go back to reference Shrewsbury S, Cook R, Taylor G et al (2008) Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO_) Inhaler. Headache 48:355–367PubMedCrossRef Shrewsbury S, Cook R, Taylor G et al (2008) Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO_) Inhaler. Headache 48:355–367PubMedCrossRef
11.
go back to reference Dodick DW, Mauskop A, Elkind AH et al (2005) Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45:315–324PubMedCrossRef Dodick DW, Mauskop A, Elkind AH et al (2005) Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45:315–324PubMedCrossRef
12.
go back to reference Mathew NT (2008) A double-blind comparison of botulinum toxin type A (BoNTA) and topiramate for the prophylactic treatment of transformed migraine headaches: a pilot study. Presented at the 12th congress of the European Federation of the European Societies: 23–26 Aug 2008, Madrid, Spain Mathew NT (2008) A double-blind comparison of botulinum toxin type A (BoNTA) and topiramate for the prophylactic treatment of transformed migraine headaches: a pilot study. Presented at the 12th congress of the European Federation of the European Societies: 23–26 Aug 2008, Madrid, Spain
13.
go back to reference Blumenfeld AM, Schim JD, Chippendale TJ (2008) Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 48:210–220PubMedCrossRef Blumenfeld AM, Schim JD, Chippendale TJ (2008) Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 48:210–220PubMedCrossRef
14.
go back to reference Allergan announces positive top-line results from phase III BOTOX headache program—Released 11 Sept 2008 0900 a.m. Eastern Daylight Time Allergan announces positive top-line results from phase III BOTOX headache program—Released 11 Sept 2008 0900 a.m. Eastern Daylight Time
Metadata
Title
New acute treatments for headache
Author
Alan M. Rapoport
Publication date
01-06-2010
Publisher
Springer Milan
Published in
Neurological Sciences / Issue Special Issue 1/2010
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-010-0304-7

Other articles of this Special Issue 1/2010

Neurological Sciences 1/2010 Go to the issue

Key Note Lecture

Migraine is curable!